Q-Line BiotechNSE:QLINE -5.15%12 Operating Margin % is 22.20% as of Mar. 2025, which is 25% above its 10-year median of 17.77. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 89.95% on this metric.
The historical rank and industry rank for Q-Line Biotech's Operating Margin % or its related term are showing as below:
NSE:QLINE'
s Operating Margin % Range Over the Past 10 Years
Min: 17.1 Med: 17.77 Max: 22.2
Current: 22.2
NSE:QLINE's Operating Margin % is ranked better than 89.95% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.4
vs NSE:QLINE: 22.20
Q-Line Biotech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Q-Line Biotech Operating Margin % Related Terms
Q-Line Biotech Operating Margin % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Operating Margin % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Operating Margin %
17.77
17.10
22.20
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Operating Margin %
17.77
17.10
22.20
NSE:QLINE vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, Q-Line Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Q-Line Biotech's Operating Margin % for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Operating Margin % of 22.20% as of Mar. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Q-Line Biotech and its competitors. This is 25% above median its historical median of 17.77. Over the past decade, Q-Line Biotech's Operating Margin % has ranged from 17.10 to 22.20. According to the industry distribution chart, Q-Line Biotech ranks #82 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 10%.
Is Q-Line Biotech's Operating Margin % too high?
Q-Line Biotech's current Operating Margin % of 22.20% is 25% above median its 10-year median of 17.77. Over the past 10 years, this metric has ranged from a low of 17.10 to a high of 22.20. The Medical Devices & Instruments industry median Operating Margin % is 3.40. Q-Line Biotech's value of 22.20% is 552.9% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #82 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #82 out of 816 companies for Operating Margin %. This places Q-Line Biotech in the top 10% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.40. Q-Line Biotech's value of 22.20% is 552.9% above this benchmark. Historically, Q-Line Biotech's own Operating Margin % has ranged from 17.10 to 22.20 over the past decade. While the company's 10-year median is 17.77 vs. the industry median of 3.40, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.40, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Operating Margin % of 22.20% is 552.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Operating Margin % is 22.20%, which is 25% above median its own 10-year median of 17.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Operating Margin % of 22.20%. The current Operating Margin % is 22.20%, which is 25% above median its 10-year median of 17.77 and 552.9% above the Medical Devices & Instruments industry median of 3.40. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Operating Margin % is 22.20% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 